• Session Overview
• Program Content
• Faculty
• Target Audience and Learning Objectives
• Continuing Pharmacy Education Credit
• BCOP Specialty Recertification Credit
• Technical Requirements
• Commercial Support
• Fees

2019 ACCP/ASHP BCOP Clinical Sessions have been approved by the Board of Pharmacy Specialties for recertification of Board Certified Oncology Pharmacy Specialists (BCOPs). The sessions are jointly sponsored by ACCP and the American Society of Health-System Pharmacists.

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants’ skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

Release date: December 18, 2019
ORIGINAL BCOP credit expiration date: June 17, 2020
EXTENDED BCOP credit expiration date: August 12, 2020
ACPE credit expiration date: October 24, 2022

The 2019 ACCP/ASHP BCOP Clinical Sessions are offered in two parts. The first part is focused on anticogulation and malignancies and the second part of the 2019 ACCP/ASHP BCOP Clinical Sessions will examine immune related adverse effects.

	Arthur L. Allen, Pharm.D., CACP Anticoagulation Program Manager VA Salt Lake City Health Care System Salt Lake City, Utah
	Joseph S. Bubalo, Pharm.D., BCPS, BCOP Oncology Clinical Pharmacy Specialist Oregon Health & Science University Hospital and Clinics Portland, Oregon
	Katerina Butler, Pharm.D., BCOP Hematology/Oncology Clinical Pharmacist VA Salt Lake City Healthcare System Salt Lake City, Utah
	Carolyn J. Oxencis, Pharm.D., BCOP Hematology/Oncology Clinical Pharmacist Froedtert and the Medical College of Wisconsin Clinical Cancer Center Milwaukee, Wisconsin
	Eve-Michelle Segal, Pharm.D., BCOP Lead Clinical Pharmacist University of Washington Medical Center/Seattle Cancer Care Alliance Clinical Instructor University of Washington School of Pharmacy Seattle, Washington
	Amy S. Sipe, R.Ph. Clinical Pharmacy Specialist Kansas City VA Medical Center Kansas City, Missouri

Clinical Pharmacists and BCOPs providing care to patients with cancer.

At the conclusion of Anticoagulation Therapy: Considerations in the Setting of Malignancy the participant should be able to:

1. Discuss the suspected pathophysiology and problem of venous thromboembolism in malignancy.
2. Describe current guidance for primary VTE prophylaxis in cancer patients.
3. Analyze existing and emerging literature regarding the application of DOACs in the treatment of venous thromboembolism in malignancy.
4. Assess issues related to DOAC use in malignancy and the impact they have on patient care.

At the conclusion of Updates in the Management of Acute, Chronic, and Refractory Immune-Related Adverse Effects of Immune Checkpoint Inhibitors the participant should be able to:

1. Describe the mechanism of action of CTLA-4, PD-1, and PD-L1 inhibitors and how their differences contribute to their respective immune-related adverse event profile.
2. Evaluate the safety and efficacy data available for current FDA approved immunotherapy agents and treatment regimens.
3. Design a customized treatment plan for a patient presenting to the acute care inpatient service with a severe or life-threatening irAE.
4. Design a customized treatment plan for a patient presenting to an ambulatory outpatient clinic with a chronic or steroid refractory irAE.
5. Reccomend effective approaches to care coordination and survivorship planning for patients who experience irAE across a healthcare system.

The American Society of Health-System Pharmacists and American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Anticoagulation Therapy: Considerations in the Setting of Malignancy
Activity Number: 0217-9999-19-160-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

Updates in the Management of Acute, Chronic, and Refractory Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
Activity Number: 0217-9999-19-172-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

Methods and CE Requirements

ACPE Continuing Pharmacy Education Credit
Activities consist of audio/video/PDF files, an attestation statement, and activity evaluation. To be eligible to earn ACPE continuing pharmacy education (CPE) credit, participants must purchase the course, review all content and complete the attestation statement and course evaluation by October 24, 2022 to receive continuing pharmacy education credit for each activity. Attestation Statements may not be submitted more than one time.

National Association of Boards of Pharmacy - CPE Monitor Service

Provided through the collaborative efforts of the National Association of Boards of Pharmacy (NABP), the Accreditation Council for Pharmacy Education (ACPE), and ACPE-accredited providers, the CPE Monitor Service allows you to electronically keep track of continuing pharmacy education (CPE) credits from ACPE-accredited providers. ACPE-accredited providers, like ACCP, are responsible for transmitting this information to NABP to be stored in the CPE Monitor system. Statements of credit will be available at CPE Monitor, nabp.pharmacy/cpe-monitor-service/, within 2–3 business days after completion of this activity. For more information on CPE Monitor please visit nabp.pharmacy/cpe-monitor-service/.

To transfer these credits to CPE Monitor on your behalf your NABP e-Profile ID Number and date of birth must be listed on your ACCP account. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Some international pharmacists do not use the CPE Monitor service. To verify or update this information in your ACCP account, visit Licensure/Certification. Check the box “I am an international pharmacist or I am not licensed to practice in the United States, and do not have an NABP e-Profile ID.” Be sure to save your changes at the bottom of the page.

To be eligible to earn BCOP recertification credit for this course you must purchase the recertification version of this course, successfully complete the course, and submit and pass the web-based posttest associated with each module by August 12, 2020. Posttests may not be submitted more than one time.

The passing point to earn BCOP recertification credit is based on an expert analysis of the assessment items in each posttest module. Any posttest submitted before the BCOP posttest deadline that meets this passing point will earn BCOP recertification credits. These credits will be assigned as of the date of test submission. For statements of recertification credit, visit www.bpsweb.org.

All participants must have a Board of Pharmacy Specialties (BPS) board certification credential number, BPS ID Number, and a BPS expiration date on file with ACCP for reporting purposes. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Questions regarding the number of hours required for BCOP recertification should be directed to BPS at (202) 946-5026 or www.bpsweb.org. The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs.

Requires an Internet browser and Adobe Reader.

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.